Advicenne S.A. (EPA:ALDVI)

Market Cap	19.12M -7.5%
Revenue (ttm)	6.40M +21.6%
Net Income	-9.53M
EPS	-0.65
Shares Out	14.55M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	68,817
Open	1.316
Previous Close	1.314
Day's Range	1.200 - 1.316
52-Week Range	0.804 - 2.350
Beta	0.98
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 17, 2026

About Advicenne

Advicenne S.A., a specialty pharmaceutical company, develops, commercializes, and markets treatments for rare renal diseases in France and internationally. It offers Sibnayal for the treatment of metabolic disorders, distal renal tubular acidosis, and cystinuria. The company also distributes Likozam, a formulation of clobazam for the treatment of short-term symptomatic of severe, disabling, or condition-causing anxiety unacceptable distress; and Levidcen, a galenic form of levetiracetam for the treatment of epileptic seizures. Advicenne S.A. wa...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2007
• Employees: 11
• Stock Exchange: Euronext Paris
• Ticker Symbol: ALDVI

Financial Performance

In 2025, Advicenne's revenue was 6.40 million, an increase of 21.56% compared to the previous year's 5.27 million. Losses were -9.53 million, 47.5% more than in 2024.